Eurofins has completed the acquisition of bioskin GmbH, a company specialising in trials for drugs, medical devices, food supplements and cosmetics. With this new operation, Eurofins carries on its strategy to diversify its clinical testing footprint in dermatology.
Over the last 30 years bioskin has built a reputation for excellence in providing clinical trials in dermatology. bioskin employs over 60 staff in its facility in Hamburg and has generated revenues of over EUR 11 million in 2020. “bioskin brings to Eurofins innovative capabilities, a strong position in early phase studies and proof-of-concept models, international multi-centre phase II– III studies, and unique expertise with its own in-house research centre,” said Eurofins in a statement.
Eurofins Cosmetics & Personal Care Testing Business line is the leading provider in cosmetics suncare and personal care testing worldwide, offering the most comprehensive range of testing and clinical services from 26 state-of-the-art laboratories in Europe, North America, Asia-Pacific and Africa and unrivalled customer service. Supported by 16 clinical laboratories, Eurofins Cosmetics & Personal Care testing offers clinical capabilities worldwide.
This acquisition is providing Eurofins with a range of complementary and extended services to support their growth and further strengthen their offering and to facilitate customer access to multicentric studies.